Acetylcholinesterase inhibitors have been given priority four in the national guidelines, and rivastigmine has been given the rating clinically useful in the international PD treatment guidelines, while donepezil, also priority four in the national guidelines, has been given the rating possibly useful in the international guidelines. The gene discussed is ACHE; the disease is Parkinson disease.